PURPOSE: To assess the value of multi-tumor marker protein chips in the diagnosis and treatment of ovarian cancer. MATERIALS AND METHODS: Twelve tumor markers (CA19-9, NSE, CEA, CA242, CK19, β-HCG, AFP, SCC, c-PSA, CA125, CA724 and CA15-3) were detected by protein biochip in 220 patients with ovarian carcinomas, 205 with benign ovarian tumors and 200 healthy subjects. RESULTS: The positivity rate was obviously higher in ovarian cancer (77.7%), than that in the benign cases (26.3%, p<0.01) and healthy subjects (4.5%, p<0.01). Serum levels of tumor markers were furthermore significantly higher in cases with lymph node metastasis (86.8%) than those without metastasis (44.7%), p<0.01. CONCLUSIONS: Multi-tumor marker protein chips provide important assistance in the diagnosis and treatment evaluation in ovarian cancers.
PURPOSE: To assess the value of multi-tumor marker protein chips in the diagnosis and treatment of ovarian cancer. MATERIALS AND METHODS: Twelve tumor markers (CA19-9, NSE, CEA, CA242, CK19, β-HCG, AFP, SCC, c-PSA, CA125, CA724 and CA15-3) were detected by protein biochip in 220 patients with ovarian carcinomas, 205 with benign ovarian tumors and 200 healthy subjects. RESULTS: The positivity rate was obviously higher in ovarian cancer (77.7%), than that in the benign cases (26.3%, p<0.01) and healthy subjects (4.5%, p<0.01). Serum levels of tumor markers were furthermore significantly higher in cases with lymph node metastasis (86.8%) than those without metastasis (44.7%), p<0.01. CONCLUSIONS:Multi-tumor marker protein chips provide important assistance in the diagnosis and treatment evaluation in ovarian cancers.